NCT04655729Completed
Biomarkers to Predict and Monitor Response to Infliximab
Detection of Serum Protein Biomarkers to Predict and Monitor Response to Infliximab Using SOMAscan
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
The aim of the study is to generate novel minimally-invasive serum protein signatures and biomarkers in children and adolescents with Crohn's Disease (CD) that correlate with and can predict and monitor patients who will have a prolonged response to Infliximab so that personalized medicine can be applied to patients with CD.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 107 (actual)
- First submitted
- 30 Nov 2020
- Start date
- 18 Nov 2019
- Primary completion date
- 30 Sept 2024
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Crohn's disease
- NCT number
- NCT04655729
What you commit to
- Study type: Observational
- Participants enrolled: 107
- From 18 Nov 2019 to the primary completion date, 30 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving infliximab or biosimilar infusions at home
- Patients already undergone significant bowel surgery relating to their Crohn's.
Who the study is looking for
- Patients between the ages of 3-20 years old
- Patient starting infliximab or infliximab biosimilar,
- Patients naïve to TNF inhibitor
Age in the registry: 3 years to 20 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MassGeneral for Children Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.